Starting Sunday, March 29th, 2020 beginning at 8:00 AM EDT, and ending on Sunday, March 29th, 2020 beginning at 12:30 AM EDT. During this time there will be no access to the EDC/Rave system. Please share this notification to the personnel who will be affected by this within your organization. Maintenance Start: Sunday, March 29th, 2020 at 8:00 AM EDT. Maintenance End: Sunday, March 29th, 2020 at 12:30 AM EDT.
We are sorry for any inconvenience this may cause.
CCTG Patient Representative Bob Taylor discusses the importance of having somebody, that's not the clinical researcher, representing what patients care about and considering the interests of the patients and their family in clinical trial design.
Bob's career as an executive in the energy sector was followed by a stint as Assistant Deputy Minister in the Alberta government and a leading not-for-profit that seeks to engage a broad spectrum of individuals in fact based conversations about future energy options. In addition to supporting the CCTG Breast Cancer Committee he remains an avid international traveler seeking to include hiking and multi-day cycling as part of the itinerary.
ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.
Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.